Obstet Gynecol Sci.  2015 Jul;58(4):284-288. 10.5468/ogs.2015.58.4.284.

Public perception of risk-reducing salpingectomy for preventing ovarian cancer

• Kang JH
• Nam SH
• Song T
• Kim WY
• Lee KW
• Kim KH

• KMID: 2314048
• DOI: http://doi.org/10.5468/ogs.2015.58.4.284

Abstract

OBJECTIVE
The fallopian tube is considered as the site of origin of serous ovarian cancer, and risk-reducing salpingectomy (RRS) has been proposed as a new and safe strategy for preventing ovarian cancer. However, little is known about the public perception of RRS.
METHODS
We performed a questionnaire survey of 100 healthy female volunteers in November 2014. Questionnaire for this survey included questions on demographics, medical history, knowledge of and belief about RRS, and barrier to its application.
RESULTS
Among 100 respondents, 71% did not realize the seriousness of ovarian cancer, 79% were unaware of the fact that salpinx was the origin of ovarian cancer, and 87% stated that they had never heard of RRS as a preventive method for ovarian cancer. Also, 98% of respondents replied that they had the right to be informed about RRS and the choice given. The respondents' fears about RRS included increased risk of surgical complications (68%), no benefit (8%), and increased surgical costs (3%).
CONCLUSION
Most general women were unaware of RRS as a method for preventing ovarian cancer in women at average risk. Therefore, physicians should discuss RRS with patients and consider this procedure at the time of abdominal or pelvic surgery.

Keyword

Data collection; Ovarian neoplasms; Public perception; Risk-reducing salpingectomy

MeSH Terms

Surveys and Questionnaires
Demography
Fallopian Tubes
Female
Humans
Ovarian Neoplasms*
Salpingectomy*
Volunteers

Reference

1. Jung KW, Won YJ, Kong HJ, Oh CM, Lee DH, Lee JS. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2011. Cancer Res Treat. 2014; 46:109–123.

2. Yun JH, Lee HY, Park HW, Shin JW, Lee JM, Park CY. The analysis of prognostic factors in patients with epithelial ovarian cancer. Korean J Obstet Gynecol. 2006; 49:566–571.

3. Goff BA, Mandel L, Muntz HG, Melancon CH. Ovarian carcinoma diagnosis. Cancer. 2000; 89:2068–2075.

4. Lurie G, Wilkens LR, Thompson PJ, Matsuno RK, Carney ME, Goodman MT. Symptom presentation in invasive ovarian carcinoma by tumor histological type and grade in a multiethnic population: a case analysis. Gynecol Oncol. 2010; 119:278–284.

5. Friedlander ML. Prognostic factors in ovarian cancer. Semin Oncol. 1998; 25:305–314.

6. Rodriguez-Ayala G, Romaguera J, Lopez M, Ortiz AP. Ovarian cancer screening practices of obstetricians and gynecologists in puerto rico. Biomed Res Int. 2014; 2014:920915.

7. Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011; 305:2295–2303.

8. Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014; 384:1376–1388.

9. Landen CN Jr, Birrer MJ, Sood AK. Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol. 2008; 26:995–1005.

10. Rosenblatt KA, Thomas DB. Lactation and the risk of epithelial ovarian cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Epidemiol. 1993; 22:192–197.

11. Casagrande JT, Louie EW, Pike MC, Roy S, Ross RK, Henderson BE. "Incessant ovulation" and ovarian cancer. Lancet. 1979; 2:170–173.

12. Cramer DW, Hutchison GB, Welch WR, Scully RE, Knapp RC. Factors affecting the association of oral contraceptives and ovarian cancer. N Engl J Med. 1982; 307:1047–1051.

13. Dubeau L. The cell of origin of ovarian epithelial tumours. Lancet Oncol. 2008; 9:1191–1197.

14. Erickson BK, Conner MG, Landen CN Jr. The role of the fallopian tube in the origin of ovarian cancer. Am J Obstet Gynecol. 2013; 209:409–414.

15. Selvaggi SM. Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament. Arch Pathol Lab Med. 2000; 124:477.

16. Chan A, Gilks B, Kwon J, Tinker AV. New insights into the pathogenesis of ovarian carcinoma: time to rethink ovarian cancer screening. Obstet Gynecol. 2012; 120:935–940.

17. Salvador S, Gilks B, Kobel M, Huntsman D, Rosen B, Miller D. The fallopian tube: primary site of most pelvic high-grade serous carcinomas. Int J Gynecol Cancer. 2009; 19:58–64.

18. Frontline Medical News. Salpingectomy associated with reduced ovarian cancer risk [Internet]. Forest Hills (NY): Frontline Medical News;c2014. cited 2015 May 29. Available from: http://www.pm360online.com/salpingectomy-associated-with-reduced-ovarian-cancer-risk.

19. Society of Gynecologic Oncology. SGO clinical practice statement: salpingectomy for ovarian cancer prevention [Internet]. Chicago (IL): Society of Gynecologic Oncology;c2013. cited 2015 May 29. Available from: http://www.sgo.org/clinical-practice/guidelines/sgo-clinical-practice-statement-salpingectomy-for-ovarian-cancer-prevention.

20. Skytte AB, Gerdes AM, Andersen MK, Sunde L, Brondum-Nielsen K, Waldstrom M, et al. Risk-reducing mastectomy and salpingo-oophorectomy in unaffected BRCA mutation carriers: uptake and timing. Clin Genet. 2010; 77:342–349.

21. Metcalfe KA, Birenbaum-Carmeli D, Lubinski J, Gronwald J, Lynch H, Moller P, et al. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer. 2008; 122:2017–2022.